title: Ibuprofen with or without an antiemetic for acute migraine headaches in adults.
abstract: BACKGROUND
  This is an updated version of the original review published in Issue 10, 2010 (Rabbie 2010). Migraine is a common, disabling condition and a burden for the individual, health services and society. Many sufferers do not seek professional help, relying instead on over-the-counter analgesics. Co-therapy with an antiemetic should help to reduce symptoms commonly associated with migraine headaches.
  
  
  OBJECTIVE
  To determine efficacy and tolerability of ibuprofen, alone or in combination with an antiemetic, compared to placebo and other active interventions in the treatment of acute migraine headaches in adults.
  
  
  METHODS
  We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Oxford Pain Relief Database, ClinicalTrials.gov, and reference lists for studies through 22 April 2010 for the original review and to 14 February 2013 for the update.
  
  
  METHODS
  We included randomised, double-blind, placebo- or active-controlled studies using self-administered ibuprofen to treat a migraine headache episode, with at least 10 participants per treatment arm.
  
  
  METHODS
  Two review authors independently assessed trial quality and extracted data. Numbers of participants achieving each outcome were used to calculate relative risk and number needed to treat (NNT) or harm (NNH) compared to placebo or other active treatment.
  
  
  RESULTS
  No new studies were found for this update. Nine included studies (4373 participants, 5223 attacks) compared ibuprofen with placebo or other active comparators; none combined ibuprofen with a self-administered antiemetic. All studies treated attacks with single doses of medication. For ibuprofen 400 mg versus placebo, NNTs for 2-hour pain-free (26% versus 12% with placebo), 2-hour headache relief (57% versus 25%) and 24-hour sustained headache relief (45% versus 19%) were 7.2, 3.2 and 4.0, respectively. For ibuprofen 200 mg versus placebo, NNTs for 2-hour pain-free (20% versus 10%) and 2-hour headache relief (52% versus 37%) were 9.7 and 6.3, respectively. The higher dose was significantly better than the lower dose for 2-hour headache relief. Soluble formulations of ibuprofen 400 mg were better than standard tablets for 1-hour, but not 2-hour headache relief.Similar numbers of participants experienced adverse events, which were mostly mild and transient, with ibuprofen and placebo.Ibuprofen 400 mg did not differ from rofecoxib 25 mg for 2-hour headache relief or 24-hour headache relief.
  
  
  CONCLUSIONS
  We found no new studies since the last version of this review. Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority. NNTs for all efficacy outcomes were better with 400 mg than 200 mg in comparisons with placebo, and soluble formulations provided more rapid relief. Adverse events were mostly mild and transient, occurring at the same rate as with placebo.
authors: Department of Respiratory Medicine, Epsom and St Helier University Hospitals NHS Trust, London, UK.
authors: Roy
authors: R
authors: Rabbie
authors: Sheena
authors: S
authors: Derry
authors: R Andrew
authors: RA
authors: Moore
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000932:Antiemetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D018712:Analgesics, Non-Narcotic; D000932:Antiemetics; D007052:Ibuprofen
references: Cephalalgia. 2008 Sep;28 Suppl 2:28-35
references: 18715330
references: Eur J Clin Pharmacol. 1983;24(6):777-85
references: 6884416
references: Br Med J (Clin Res Ed). 1988 May 7;296(6632):1313-6
references: 3133061
references: Br J Clin Pharmacol. 1975 Feb;2(1):57-63
references: 791318
references: J Headache Pain. 2012 Jul;13(5):361-78
references: 22644214
references: Rev Neurol. 2008 Nov 16-30;47(10):506-8
references: 19012253
references: Cephalalgia. 2000 May;20(4):233-43
references: 10999673
references: Headache. 2001 Jul-Aug;41(7):665-79
references: 11554954
references: Cephalalgia. 2004;24 Suppl 1:9-160
references: 14979299
references: Cephalalgia. 2000 Nov;20(9):765-86
references: 11167908
references: Ann Pharmacother. 2007 Nov;41(11):1782-91
references: 17878396
references: Headache. 2012 Apr;52(4):582-91
references: 22590713
references: Br Med J. 1974 Nov 2;4(5939):265-8
references: 4425854
references: Cephalalgia. 2004 Nov;24(11):947-54
references: 15482357
references: J Headache Pain. 2010 Aug;11(4):289-99
references: 20473702
references: Clin J Pain. 2009 Oct;25(8):696-8
references: 19920719
references: Ann Emerg Med. 1993 Feb;22(2):191-5
references: 8427430
references: Headache. 2009 Apr;49(4):498-508
references: 19245386
references: Lancet. 2012 Dec 15;380(9859):2163-96
references: 23245607
references: J Headache Pain. 2007 Jun;8(3):175-9
references: 17563841
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008041
references: 23633350
references: Headache. 2006 Feb;46(2):264-75
references: 16492236
references: Cephalalgia. 1992 Jun;12(3):169-71; discussion 128
references: 1623513
references: Headache. 1989 Sep;29(8):507-9
references: 2676908
references: Int J Clin Pharmacol Res. 1998;18(3):145-50
references: 9825271
references: BMJ. 1995 Feb 18;310(6977):452-4
references: 7873954
references: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD001548
references: 19588326
references: Cephalalgia. 2012 Apr;32(5):373-81
references: 22395797
references: Cochrane Database Syst Rev. 2010 Oct 06;(10):CD008039
references: 20927770
references: Value Health. 2009 Jan-Feb;12(1):55-64
references: 18671771
references: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004604
references: 19821329
references: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008783
references: 23633360
references: BMJ. 1997 Sep 13;315(7109):635-40
references: 9310564
references: Ann Intern Med. 1987 Aug;107(2):224-33
references: 3300460
references: Pain. 2002 Jun;97(3):247-257
references: 12044621
references: Headache. 2007 Mar;47(3):355-63
references: 17371352
references: Neurology. 2007 Jan 30;68(5):343-9
references: 17261680
references: Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008615
references: 22336849
references: Neurology. 2005 Feb 8;64(3):463-8
references: 15699376
references: Postgrad Med J. 2004 Dec;80(950):720-3
references: 15579612
references: Cephalalgia. 2010 Sep;30(9):1065-72
references: 20713557
references: Cephalalgia. 1988;8 Suppl 7:1-96
references: 3048700
references: Cephalalgia. 1995 Dec;15(6):531-5
references: 8706118
references: Headache. 2012 Jan;52(1):3-17
references: 22106869
references: Neurology. 2008 Aug 19;71(8):559-66
references: 18711108
references: Headache. 2006 May;46(5):715-25
references: 16643573
references: Pain. 1996 Aug;66(2-3):239-46
references: 8880846
references: J Headache Pain. 2005 Dec;6(6):429-40
references: 16388337
references: Headache. 2009 Jan;49(1):79-89
references: 19125877
references: Headache. 2006 Mar;46(3):444-53
references: 16618262
references: J Headache Pain. 2013 Jan 10;14:1
references: 23566305
references: Pain. 1998 Dec;78(3):209-216
references: 9870574
references: Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008040
references: 23633349
references: Eur J Neurol. 2012 May;19(5):703-11
references: 22136117
references: Practitioner. 1983 Mar;227(1377):465-7
references: 6351046
references: Pain. 1997 Aug;72(1-2):95-7
references: 9272792